scholarly journals Activation of the type I interferon system in primary Sjögren's syndrome: A possible etiopathogenic mechanism

2005 ◽  
Vol 52 (4) ◽  
pp. 1185-1195 ◽  
Author(s):  
Ullvi Båve ◽  
Gunnel Nordmark ◽  
Tanja Lövgren ◽  
Johan Rönnelid ◽  
Stefan Cajander ◽  
...  
Keyword(s):  
Type I Interferon ◽  
Sjögren's Syndrome ◽  
Sjogren’S Syndrome ◽  
Sjogren's Syndrome ◽  
Primary Sjögren’S Syndrome ◽  
Type I ◽  
Primary Sjogren’S Syndrome ◽  
Primary Sjögren's Syndrome ◽  
Interferon System ◽  
Sjögren‘S Syndrome

Increased frequency of the PTPN22W* variant in primary Sjogren's Syndrome: Association with low type I IFN scores

2016 ◽  
Vol 173 ◽  
pp. 157-160 ◽  
Author(s):  
Nikolaos I. Vlachogiannis ◽  
Adrianos Nezos ◽  
Athanasios G. Tzioufas ◽  
Michael Koutsilieris ◽  
Haralampos M. Moutsopoulos ◽  
...  
Keyword(s):  
Sjögren's Syndrome ◽  
Sjogren’S Syndrome ◽  
Sjogren's Syndrome ◽  
Primary Sjögren’S Syndrome ◽  
Type I ◽  
Type I Ifn ◽  
Primary Sjogren’S Syndrome ◽  
Primary Sjögren's Syndrome ◽  
Syndrome Association ◽  
Sjögren‘S Syndrome

Contrasting expression pattern of RNA-sensing receptors TLR7, RIG-I and MDA5 in interferon-positive and interferon-negative patients with primary Sjögren's syndrome

2016 ◽  
Vol 76 (4) ◽  
pp. 721-730 ◽  
Author(s):  
Naomi I Maria ◽  
Eline C Steenwijk ◽  
Arne S IJpma ◽  
Cornelia G van Helden-Meeuwsen ◽  
Petra Vogelsang ◽  
...  
Keyword(s):  
Expression Pattern ◽  
Sjögren’S Syndrome ◽  
Sjögren's Syndrome ◽  
Sjogren’S Syndrome ◽  
Sjogren's Syndrome ◽  
Primary Sjögren’S Syndrome ◽  
Type I ◽  
Primary Sjogren’S Syndrome ◽  
Primary Sjögren's Syndrome ◽  
Sjögren‘S Syndrome

ObjectiveThe interferon (IFN) type I signature is present in over half of patients with primary Sjögren's syndrome (pSS) and associated with higher disease-activity and autoantibody presence. Plasmacytoid dendritic cells (pDCs) are considered as the main source of enhanced IFN type I expression. The objective of this study was to unravel the molecular pathways underlying IFN type I bioactivity in pDCs of patients with pSS.MethodsBlood samples from 42 healthy controls (HC) and 115 patients with pSS were stratified according to their IFN type I signature. CD123+BDCA4+ pDCs and CD14+ monocytes were isolated from peripheral blood mononuclear cells (PBMCs). Genome-wide microarray analysis was conducted on sorted pDCs in a small sample set, followed by validation of differentially expressed genes of interest in pDCs and monocytes.ResultsWe found an upregulation of endosomal toll-like receptor (TLR) 7, but not TLR9, in IFN-positive (IFNpos) pDCs (p<0.05) and monocytes (p=0.024). Additionally, the downstream signalling molecules MyD88, RSAD2 and IRF7 were upregulated, as were the cytoplasmic RNA-sensing receptors DDX58/retinoic acid inducible gene-I (RIG-I) and IFIH1/melanoma differentiation associated gene-5 (MDA5). In vitro triggering of the TLR7-pathway in HC PBMCs induced upregulation of DDX58/RIG-I and IFIH1/MDA5, and downregulated TLR9. The upregulation of TLR7, its downstream signalling pathway, DDX58/RIG-I and IFIH1/MDA5 were confined to patients with IFN-positive pSS. IFN-negative patients had a contrasting expression pattern—TLR7 normal, and decreased TLR9, RIG-I and MDA5.ConclusionsHere we conclude a contrasting expression pattern of the RNA-sensing receptors TLR7, RIG-I and MDA5 in pDCs and monocytes of patients with IFNpos pSS. This profile could explain the pathogenic IFN production and might reveal novel therapeutic targets in these patients.

Sign in / Sign up

Export Citation Format

Share Document